April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatment
April 17th 2015Abnormal driver mutations contribute to tumor progression and have been prime targets for many therapeutic studies in oncology; however, researchers are focusing more and more on the less-studied passenger mutations and their role in tumor progression.
Read More
The Role of Macrophages in BRAF Inhibitor Resistance
April 15th 2015Turning their experimental focus on the tumor microenvironment, the authors of a paper published in Clinical Cancer Research have shed light on the role of melanoma-associated tumor macrophages in resistance to BRAF V600E inhibitors.
Read More
Tumor Antigens and Their Role in Immune Response in Melanoma
March 24th 2015Melanoma is the most deadly skin cancer. According to data collected between 2004 and 2010, only 16% of Americans with metastatic melanoma, including people of all ages and races, and both genders, survive for 5 years or more after diagnosis.
Read More
Thyroiditis in Melanoma Patient Treated With Ipilimumab and Pembrolizumab
March 7th 2015In an analysis of adverse events following treatment of patients with advanced melanoma with ipilimumab and nivolumab, combination therapy was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis.
Read More
Genetic and Epigenetic Biomarkers in Melanoma Prognosis and Treatment
February 4th 2015Epigenetic and genetic biomarkers are potential methods of early detection of melanoma and other types of skin cancer. Earlier diagnosis alone would improve survival, even in the absence of novel therapies.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
Combined Inhibition of BRAF and MEK Improves Progression-Free Survival in BRAF-Mutated Melanoma
January 10th 2015Reported results from the coBRIM study have shown that combining the BRAF inhibitor vemurafenib with cobimetinib, a MEK inhibitor, increases progression-free survival (PFS) in patients with BRAF-mutated advanced melanoma compared with vemurafenib alone.
Read More
An Immunostimulatory, Targeted Cytotoxic Medication for Skin Cancer: Aviscumine
January 9th 2015Cytavis Biopharma GmbH, a Germany-based pharmaceutical company, is developing a natural protein, aviscumine (CY-503), as an immunostimulatory agent to improve response to immunotherapeutic treatment of melanoma.
Read More
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration
January 6th 2015Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Read More
CAR T-Cell Therapy CTL019 Demonstrates 92% Response Rate in Pediatric ALL
December 7th 2014The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More